KBY Biotech Indexv0.0.34
Search
← Pipeline|SCI-9998

SCI-9998

Approved
By Scientus Pharma
Source: Trial-derived·Trials: 2
Modality
Small Molecule
MOA
FXIai
Target
USP1
Pathway
Angiogenesis
Prostate Ca
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
~Jan 2018
→ ~Apr 2019
Phase 2
~Jul 2019
→ ~Oct 2020
Phase 3
~Jan 2021
→ ~Apr 2022
NDA/BLA
~Jul 2022
→ ~Oct 2023
Approved
Jan 2024
→ Feb 2028
ApprovedCurrent
NCT03553295
1,238 pts·Prostate Ca
2024-01→2025-12·Active
NCT08711564
1,366 pts·Prostate Ca
2024-03→2028-02·Completed
2,604 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2025-12-223mo agoPh3 Readout· Prostate Ca
2028-02-171.9y awayPh3 Readout· Prostate Ca
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
Approved
Active
Approved
Complet…
Catalysts
Ph3 Readout
2025-12-22 · 3mo ago
Prostate Ca
Ph3 Readout
2028-02-17 · 1.9y away
Prostate Ca
ActiveCompleted|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT03553295ApprovedProstate CaActive1238PANSS
NCT08711564ApprovedProstate CaCompleted1366ACR20
Competitors (10)
DrugCompanyPhaseTargetMOA
NVS-6360NovartisApprovedCD38FXIai
MRK-3745Merck & CoPhase 2WRNFXIai
ABB-2476AbbViePhase 1/2USP1FcRni
AZN-1715AstraZenecaPhase 3AHRFXIai
BMY-9931Bristol-Myers SquibbPhase 1GPRC5DFXIai
NVO-7877Novo NordiskPreclinicalGPRC5DFXIai
TAK-8730TakedaPhase 2VEGFFXIai
SemazasiranBeiGenePhase 1PD-1FXIai
PexanesiranUnited TherapeuticsPhase 1BCMAFXIai
NUV-283NuvalentPhase 3B7-H3FXIai